Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)
暂无分享,去创建一个
J. Burke | N. Bartlett | H. Prince | G. Rossi | B. Hess | J. Abramson | R. Lynch | H. Lee | U. Hahn | D. Straus | H. Shah | M. Gandhi | Y. Linhares | R. Mowat | C. Yasenchak | L. Ho | Steven R. Schuster | Domingo Domenech Eva | R. Ramchandren | W. Guo